EVO-756 is under clinical development by Evommune and currently in Phase I for Chronic Urticaria Or Hives. According to GlobalData, Phase I drugs for Chronic Urticaria Or Hives have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how EVO-756’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EVO-756 overview
EVO-756 is under development for the treatment of chronic pruritus, urticaria, atopic dermatitis and unspecified indication. It is administered through oral route and acts by antagonizing mas related G protein coupled receptor member X2 (MRGPRX2) antagonist.
It was under development for the treatment of interstitial cystitis.
Evommune overview
Evommune is a biotechnology company that discovers and develops therapies to treat immune-mediated inflammatory diseases. The company’s product pipeline includes EVO756, Evommune’s MRGPRX2 antagonist, which is an investigational therapy targeting MRGPRX2 for various inflammatory conditions. It also develops Protein Kinase C Theta (PKC?) inhibitor to reduce T-cell mediated inflammation. Evommune product candidates are used in treating various diseases including chronic spontaneous urticaria, atopic dermatitis (AD), inflammatory itch, psoriasis and inflammatory bowel diseases. The company was funded by Amplitude, Andera Partners, Arix, EQT, Pivotal Life Sciences, SymBiosis and Verition Fund Management. It operates with an additional office in New York, the US. Evommune is headquartered in Palo Alto, California, the US.
For a complete picture of EVO-756’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
